Skip to main content
. 2024 Feb 9;4(5):1786–1800. doi: 10.1021/jacsau.3c00682

Figure 5.

Figure 5

UCM-13369 has efficacy against AML cell lines and primary cells. (A) Dose–response curve of UCM-13369 in colony-forming unit (CFU) assays performed with primary HSCs bone marrow mononuclear fraction from healthy donors and AML patients. (B) Left: Dose–response curve of UCM-13369 in short-term cultures of HSCs performed with primary HSCs from bone marrow mononuclear fraction from healthy donors and AML patients. Right: Dose–response curve of the same assay with samples from AML patients with NPM1 WT vs NPM1 C+. (C) Dot plot of a representative sample from flow cytometry analysis using CD34-PE/Annexin V-FITC staining of short-term cultures of primary HSCs from AML patients performed with primary HSCs from bone marrow mononuclear fraction with and without treatment.